Sage TherapeuticsSAGE
SAGE
About: Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
Employees: 487
0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 9 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
155% more call options, than puts
Call options by funds: $3.95M | Put options by funds: $1.55M
27% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 51
8.74% less ownership
Funds ownership: 93.23% [Q2] → 84.49% (-8.74%) [Q3]
9% less funds holding
Funds holding: 192 [Q2] → 175 (-17) [Q3]
38% less capital invested
Capital invested by funds: $609M [Q2] → $375M (-$234M) [Q3]
50% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 32
Research analyst outlook
9 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$4
42%
downside
Avg. target
$10.89
57%
upside
High target
$26
275%
upside
9 analyst ratings
4 positive
44%
5 neutral
56%
0 negative
0%
Piper Sandler David Amsellem 58% 1-year accuracy 23 / 40 met price target | 30%upside $9 | Overweight Maintained | 2 Jan 2025 |
Stifel Paul Matteis 14% 1-year accuracy 2 / 14 met price target | 14%downside $6 | Hold Maintained | 16 Dec 2024 |
TD Cowen Ritu Baral 25% 1-year accuracy 2 / 8 met price target | 30%upside $9 | Hold Maintained | 21 Nov 2024 |
RBC Capital Brian Abrahams 10% 1-year accuracy 8 / 79 met price target | 42%downside $4 | Sector Perform Upgraded | 21 Nov 2024 |
HC Wainwright & Co. Douglas Tsao 31% 1-year accuracy 54 / 173 met price target | 102%upside $14 | Neutral Reiterated | 20 Nov 2024 |
Financial journalist opinion
Based on 26 articles about SAGE published over the past 30 days
Positive
Zacks Investment Research
1 week ago
Sage Therapeutics (SAGE) Moves 35.1% Higher: Will This Strength Last?
Sage Therapeutics (SAGE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Neutral
Accesswire
1 week ago
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Shareholders to Reach Out
NEW YORK CITY, NY / ACCESSWIRE / January 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE). Investors who purchased Sage securities prior to April 12, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAGE.
Positive
Zacks Investment Research
1 week ago
Biogen Offers to Buy Remaining Stake in Sage Therapeutics
Biogen offers to buy the remaining stake in Sage Therapeutics for $7.22 per share. SAGE stock rises.
Positive
Proactive Investors
1 week ago
Sage Therapeutics shares surge on unsolicited takeover bid from Biogen
Sage Therapeutics (NASDAQ:SAGE) stock soared after the firm announced that it had received an unsolicited takeover bid from Biogen Inc (NASDAQ:BIIB, ETR:IDP). Biogen has proposed to acquire all of Sage's shares that it does not already own for $7.22 per share.
Positive
Schaeffers Research
1 week ago
Sage Therapeutics Stock Headed for Best Day in 5 Years
Biotech stock Sage Therapeutics Inc (NASDAQ:SAGE) is skyrocketing today, up 33.7% to trade at $7.42 at last glance, after Biogen's (BIIB) proposed takeover, which the company said on Friday it would carefully review.
Positive
Investopedia
1 week ago
Sage Therapeutics Stock Soars as Biogen Makes Unsolicited Takeover Bid
Sage Therapeutics (SAGE) shares soared nearly 40% Monday on news Biogen (BIIB) is offering to buy the rest of the Sage stock it doesn't already own for $7.22 per share.
Neutral
Accesswire
1 week ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Shareholders to Learn More About the Investigation
NEW YORK CITY, NY / ACCESSWIRE / January 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE). Investors who purchased Sage securities prior to April 12, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAGE.
Positive
Benzinga
1 week ago
Why Is Depression-Focused Sage Therapeutics Stock Surging Higher On Monday?
On Friday, Sage Therapeutics Inc. SAGE confirmed that Biogen Inc. BIIB submitted an unsolicited, nonbinding proposal to acquire all of the outstanding shares of Sage Therapeutics not already owned by Biogen for $7.22 per share.
Positive
Barrons
1 week ago
Sage Therapeutics Stock Rockets 35% Higher After Takeover Bid From Biogen
The biopharmaceutical company says its board of directors will now review and evaluate the offer from Biogen.
Neutral
Business Wire
1 week ago
Sage Therapeutics to Present 2025 Strategic Focus at 43rd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) today announced that Chief Executive Officer Barry Greene will discuss the Company's strategic focus areas for 2025 at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California. As part of this presentation, Mr. Greene will discuss the ongoing commercialization and strategic growth plans for ZURZUVAE® (zuranolone), the first and only once-daily 14-day oral treatment for adults with postpartum depressi.
Charts implemented using Lightweight Charts™